Fate Therapeutics (Nasdaq:FATE) - Aktienkurs, Nachrichten und Analyse

FATE Aktienübersicht

Fate Therapeutics, Inc., ein biopharmazeutisches Unternehmen in der klinischen Phase, entwickelt programmierte zelluläre Immuntherapien für Krebs und Immunkrankheiten weltweit.

Über das Unternehmen

FATE grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	2/6
Künftiges Wachstum	2/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	6/6
Dividenden	0/6

Belohnungen

Prognostiziertes jährliches Umsatzwachstum 34.32%

Risikoanalyse

Die Erträge werden in den nächsten 3 Jahren voraussichtlich um durchschnittlich 6.2% pro Jahr sinken.

Derzeit unrentabel und in den nächsten 3 Jahren nicht rentabel zu werden prognostiziert

Die Aktionäre wurden im vergangenen Jahr verwässert

Fate Therapeutics, Inc. Wettbewerber

Avid Bioservices

NasdaqCM:CDMO

US$472.3m

Anika Therapeutics

NasdaqGS:ANIK

US$385.3m

Absci

NasdaqGS:ABSI

US$393.5m

Kyverna Therapeutics

NasdaqGS:KYTX

US$320.8m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Fate Therapeutics
Historische Aktienkurse
Aktueller Aktienkurs	US$3.59
52-Wochen-Hoch	US$8.83
52-Wochen-Tief	US$1.63
Beta	1.9
11 Monat Veränderung	-2.97%
3 Monate Veränderung	-45.69%
1 Jahr Veränderung	-31.75%
33 Jahre Veränderung	-95.77%
5 Jahre Veränderung	-82.44%
Veränderung seit IPO	-45.77%

Aktuelle Nachrichten und Updates

Fate Therapeutics: Looking For A Potential Turnaround In 2024

Apr 29

Recent updates

Fate Therapeutics: Looking For A Potential Turnaround In 2024

Apr 29

Fate Therapeutics, Inc.'s (NASDAQ:FATE) 28% Dip In Price Shows Sentiment Is Matching Revenues

Apr 23

Fate Therapeutics, Inc. (NASDAQ:FATE) Held Back By Insufficient Growth Even After Shares Climb 57%

Feb 16

Fate Therapeutics Update: A Rally Based On Little Increases Near-Term Risks

Jan 26

Fate Therapeutics, Inc.'s (NASDAQ:FATE) Shares Bounce 30% But Its Business Still Trails The Industry

Dec 19

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Deliver On Growth Plans?

Sep 08

Benign Growth For Fate Therapeutics, Inc. (NASDAQ:FATE) Underpins Its Share Price

Jun 07

Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 41%

May 08

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

Apr 17

We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully

Jan 10

Here's Why We're Not Too Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation

Sep 22

Fate Therapeutics: Yes For Speculators, No For Defensive Investors

Aug 30

Needham initiates Fate coverage Therapeutics on potential of stem cell therapies

Jul 28

Aktionärsrenditen

	FATE	US Biotechs	US Markt
7D	-4.5%	-1.3%	0.4%
1Y	-31.7%	7.7%	22.9%

Rendite im Vergleich zur Industrie: FATE unter dem Niveau der Branche US Biotechs , die im vergangenen Jahr eine Rendite von 5.5% erzielte.

Rendite vs. Markt: FATE hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 22.3 erzielte.

Preisvolatilität

Is FATE's price volatile compared to industry and market?
FATE volatility
FATE Average Weekly Movement	8.9%
Biotechs Industry Average Movement	10.5%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	2.9%

Stabiler Aktienkurs: FATEDer Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: FATEDie wöchentliche Volatilität (9%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2007	181	J. Wolchko	www.fatetherapeutics.com

Fate Therapeutics, Inc. ist ein biopharmazeutisches Unternehmen in der klinischen Phase und entwickelt programmierte zelluläre Immuntherapien für Krebs- und Immunkrankheiten weltweit. Zu den Produktkandidaten des Unternehmens, die auf chimäre Antigenrezeptoren (CAR) zur Behandlung von NK- und T-Zellen abzielen, gehören FT576 zur Behandlung des Multiplen Myeloms und FT522 zur Behandlung von Lymphomen und Autoimmunkrankheiten. Zu seinen CAR-T-Zell-Programmen gehören FT819 zur Behandlung von hämatologischen Malignomen und soliden Tumoren sowie FT825 zur Behandlung solider Tumoren.

Fate Therapeutics, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Fate Therapeutics im Vergleich zum Marktanteil des Unternehmens?
FATE grundlegende Statistiken
Marktanteil	US$388.17m
Gewinn(TTM)	-US$190.05m
Umsatz(TTM)	US$6.48m

63.1x

Kurs-Umsatz-Verhältnis

-2.2x

Kurs-Gewinn-Verhältnis

Ist FATE zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
FATE Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$6.48m
Kosten der Einnahmen	US$128.21m
Bruttogewinn	-US$121.73m
Sonstige Ausgaben	US$68.32m
Umsatz	-US$190.05m

Zuletzt gemeldete Gewinne

Mar 31, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-1.67
Bruttomarge	-1,879.08%
Nettogewinnspanne	-2,933.79%
Schulden/Eigenkapital-Verhältnis	0%

Wie hat sich FATE auf lange Sicht entwickelt?

Historische Performance und Vergleiche

FATE Aktienübersicht

Belohnungen

Risikoanalyse

Fate Therapeutics, Inc. Wettbewerber

NasdaqCM:CDMO

US$472.3m

NasdaqGS:ANIK

US$385.3m

NasdaqGS:ABSI

US$393.5m

NasdaqGS:KYTX

US$320.8m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Fate Therapeutics, Inc. Appoints J. Scott Wolchko as Principal Financial and Accounting Officer

Consensus revenue estimates increase by 32%

Price target decreased by 7.7% to US$7.20

First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Fate Therapeutics: Looking For A Potential Turnaround In 2024

Fate Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

Recent updates

Fate Therapeutics, Inc. Appoints J. Scott Wolchko as Principal Financial and Accounting Officer

Consensus revenue estimates increase by 32%

Price target decreased by 7.7% to US$7.20

First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Fate Therapeutics: Looking For A Potential Turnaround In 2024

Fate Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

Fate Therapeutics, Inc.'s (NASDAQ:FATE) 28% Dip In Price Shows Sentiment Is Matching Revenues

Fate Therapeutics, Inc. Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting

Fate Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $79.999997 million.

Fate Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $79.999997 million.

New minor risk - Shareholder dilution

Fate Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $79.999997 million.

Consensus revenue estimates decrease by 21%, EPS upgraded

Price target increased by 19% to US$7.53

Full year 2023 earnings: EPS exceeds analyst expectations

Fate Therapeutics, Inc. (NASDAQ:FATE) Held Back By Insufficient Growth Even After Shares Climb 57%

Fate Therapeutics, Inc. to Report Q4, 2023 Results on Feb 26, 2024

Fate Therapeutics Update: A Rally Based On Little Increases Near-Term Risks

Founder recently sold US$63k worth of stock

Founder notifies of intention to sell stock

Fate Therapeutics, Inc. Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors

Fate Therapeutics, Inc.'s (NASDAQ:FATE) Shares Bounce 30% But Its Business Still Trails The Industry

Price target decreased by 11% to US$6.50

General Counsel & Corporate Secretary notifies of intention to sell stock

Price target decreased by 8.8% to US$6.63

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Fate Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New minor risk - Share price stability

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Deliver On Growth Plans?

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Fate Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Yu-Waye (Wayne) Chu Intends to Resign as Chief Medical Officer of Fate Therapeutics, Inc. Effective as of July 14, 2023

Benign Growth For Fate Therapeutics, Inc. (NASDAQ:FATE) Underpins Its Share Price

Consensus revenue estimates increase by 36%

Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 41%

Fate Therapeutics, Inc. Provides Earnings Guidance for the Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

Consensus revenue estimates increase by 54%, EPS downgraded

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Fate Therapeutics, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Gainey Mckenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Fate Therapeutics, Inc

Founder recently sold US$241k worth of stock

We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully

Now 40% undervalued after recent price drop

Fate Therapeutics, Inc. Expects to Terminate Mark Plavsic as Chief Technical Officer, Effective as of March 6, 2023

Price target decreased to US$59.15

Price target decreased to US$61.10

Fate Therapeutics Announces Clinical Safety and Activity Data of First-Ever iPSC-Derived Car T-Cell Therapy

Insufficient new directors

Price target decreased to US$66.29

Third quarter 2022 earnings released: US$0.86 loss per share (vs US$0.45 loss in 3Q 2021)

Here's Why We're Not Too Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation

Fate Therapeutics: Yes For Speculators, No For Defensive Investors

Chief Financial Officer recently sold US$153k worth of stock

Price target decreased to US$74.05

Consensus forecasts updated

Fate Therapeutics Announces Preclinical Publication Highlighting Derivation of CD8aß T Cells from TCR-CAR+ Induced Pluripotent Stem Cells

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Erträge & Einnahmen